ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет Архив журнала 2000 год № 5-6

Автономия при эндемическом зобе

В. Corvilain1,2, J. Van Sande1, J.E. Dumont1,2, P.Bourdoux3, A.M. Ermans4
1 Институт междисциплинарных исследований. Школа медицины.
2 Отдел эндокринологии Госпиталя Эразма
3 Лаборатория педиатрии. Госпиталь Брагман
4 Радиоизотопное отделение, Госпиталь Св. Петра, Брюссельский Университет, Брюссель, Бельгия.
Эта статья является частью трудов симпозиума по индуцированному йодом тиреотоксикозу, Бруклайн, МА, март 1996. На русском языке статья впервые опубликована в 1999 году в сборнике "Преодоление последствий дефицита йода: зарубежный опыт" при поддержке детского фонда ООН (ЮНИСЕФ) под редакцией Г.А. Герасимова



ЛИТЕРАТУРА

  1. Burgi H., Supersaxo Z., Selz B. Iodine deficiency diseases in Switzerland after Theodor Kocher's survey. A historical review with some new goitre prevalence data.// Acta Endocrinol (Copenh) – 1990 - 123:577-590.
  2. Coindet J.F. Nouvelles recherches sur les effets de 1'iode et les precautions a suivre dans ie traitement du goitre par ie nouveau remede. // Bibi Univ Sci Belles Lettres Arts. - 1821 - 16:140.
  3. Fradkin J.E.,Wolff J. 1981 Iodine induced thyrotoxicosis. Medicine (Baltimore) 62:1-20.
  4. Beckers С. 1985 Frequency of iodide-induced thyrotoxicosis after iodine administration. In: Hall R, Kobberling J (eds.) Thyroid Disorders Associated with Iodine Deficiency and Excess. Raven Press, New York, pp. 369-382.
  5. Vidor Gl, Stewart JC, Wall JR, Wangel A, Hetzel BS. 1973 Pathogenesis of iodine-induced thyrotoxicosis: studies in Northern Tasmania. J Clin Endocrinol Metab 37:901-909.
  6. Baltisberger BL, Minder CE, Burgi H. 1995 Decrease of incidence of toxic nodular goitre in a region of Switzerland after full correction of mild iodine deficiency. Eur J Endocrinol 132:546-549.
  7. Lamberg BA. 1985 Effectiveness of iodized salt in various parts of the world. In: Hall R, Kobberling J (eds) Thyroid Disorders Associated with Iodine Deficiency and Excess. Raven Press, New York, pp. 81 -94.
  8. Ermans AM, Mugisho S, Tonglet R, Mukalay WA, Tshibangu M, Bourdoux P. 1994 Thyrotoxicosis by the consumption of highly iodinated salt in a severely iodine deficient population in Kivu. J Endocrinol Invest 17:71.
  9. Ermans AM, Gullo D, Mugisho SG, Tshibangu M, Tonglet R. 1995 Iodine supplementation must be monitored at the population level in iodine deficient areas. Thyroid 5:272.
  10. Bourdoux P, Ermans AM, Mukalay WA, Filetti S, Vigneri R. 1996 Iodine induced thyrotoxicosis in Kivu Zaire. Lancet 347:552-553.
  11. Todd Сh, Allain T, Gomo ZAR, Hasier JA, Ndiweni M, Oken E. 1995 Increase in thyrotoxicosis associated with iodine supplements in Zimbabwe. Lancet 346:1563.
  12. Demeester-Mirkine N, Ermans AM. 1967 Euthyroid "hot" nodules, a physiological approach. In: Irvine W (eds.) Thyrotoxicosis. Livingstone, Edinburgh, pp. 68-75.
  13. Hamburger JI. 1980 Evolution of toxicity in solitary non-toxic autonomously functioning thyroid nodules. J Endocrinol Metab 50:1089-1093.
  14. Hay ID, Morris JC. 1991 Autonomously functioning thyroid nodules In: Braverman LE, Utiger R (eds) The Thyroid, 6th edition, Lippincott, Philadelphia, pp. 698 – 704.
  15. Ermans AM, Camus M. 1972 Modifications of thyroid function induced by chronic administration of iodide in the presence of "autonomous" thyroid tissue. Acta Endocrinol (Copenh) 70:463-475.
  16. Livadas DP, Koutras DA, Souvatzogiou A, Beckers С. 1977 the Toxic effects of small iodine supplements in patients with autonomous thyroid nodules. Clin Endocrinol 7:121-127.
  17. Joseph К, Mahlstedt J, Gonnerman R, Herbert K, Weleke U. 1980 Early recognition and evaluation of the risk of hyperthyroidism in thyroid autonomy in an endemic goiter area. J Mol Med 4:21-37.
  18. Ernrich D, Karkavitsas N, Faorro U, Schurnbrand P, Schreivogel I, Schicha H, Dirks H. 1982 Influence of increasing iodine intake on euthyroid and hyperthyroid states. J Clin Endocrinol Metab 54:1236-1241.
  19. Roti E, Vagenakis AG. 1996 Effects of iodide excess: clinical aspects. In: Braverman LE, Utiger RD (eds.) The Thyroid, 7th edition, Lippincott, Philadelphia, pp. 316-327.
  20. Bachtarzi H, Benmiloud M 1983 TSH regulation and goitrogenesis in severe iodine deficiency. Acta Endocrinol 103: 21-27.
  21. Studer H, Peter HJ, Gerber H. 1985 Toxic nodular goitre. Clin Endocrinol Metab 14:351-372.
  22. Ermans AM, Dumont JE, Bastenie P. 1963 Thyroid function in a goiter endemic I. Impairment of hormonal synthesis and secretion in the goitrous. J Clin Endocrinol Metab 23:539-549.
  23. Wolff J. 1989 Excess iodide inhibits the thyroid by multiple mechanisms. Adv Exp Med Biol 261:211-244.
  24. Brabant G, Bergmann P, Kirsh CM, Kohrie J, Hesch RD, von Zur Muhlen A. 1992 Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man. Metabolism 41:1093-1096.
  25. Medeiros-Neto GA, Walfish PG, Almeida F, Maia E, Gomes EF, Kiy Y, Knobel M, Ginsberg J, Copra U. 1978 3,3',5'-triiodothyronine, thyroxine, triiodothyronine, and thyrotropin levels in maternal and cord blood sera from endemic goiter regions of Brazil. J Clin Endocrinol Metab 47:508-511.
  26. Dumont JE, Lamy F, Roger P, Maenhaut С. 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 72:667-697.
  27. Tramontane D, Veneziani BM, Lombard A, Villone G, Ingbar SH. 1989 Iodine inhibits the proliferation of rat thyroid cells in culture. Endocrinology 125:984-992.
  28. Roger P, Taton M, Van Sande J, Dumont JE. 1988 Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 66:1158-1165.
  29. Raspe E, Dumont JE. 1995 Tonic modulation of dog thyrocyte H202 generation and I-uptake by thyrotropin through the cyclic adenosine 3',5'-monophosphate cascade. Endocrinology 136:965-973.
  30. Vassart G, Dumont JE. 1992 The thyrotropin receptor and the regulation of thyrocyte function and growth. EndocrRev 13:596-611.
  31. Jin S, Homicek FJ, Neylan D, Zakarija M, McKenzie JM. 1986 Evidence that adenosine 3',5'-monophosphate mediates stimulation of thyroid growth in FRTL5 cells- Endocrinology 119:802-810.
  32. Corvilain В, Laurent E, Lecornte M, Van Sande J, Dumont JE. 1994 Role of the cyclic adenosine 3',5'-monophosphate and the phosphati-dylinositol-Ca2+ cascades in mediating the effects of thyrotropin and iodide on hormone synthesis and secretion in human thyroid slices. J Clin Endocrinol Metab 79:152-159.
  33. Laurent E, Mockel J, Van Sande J, Graft I, Dumont JE. 1987 Dual activation by thyrotropin of the phospholipase С and cyclic AMP cascades in human thyroid. Mol Cell Endocrinol 52:273-278.
  34. Mockel J, Laurent E, Lejeune C, Dumont JE. 1991 Thyrotropin does not activate the phosphatidylinositol bisphosphate hydrolyzing phospholipase С in the dog thyroid. Mol Cell Endocrinol 82:221-227.
  35. Laurent E, Van Sande J, Ludgate M, Corvilain B, Rocmans P, Dumont JE, Mockel J. 1991 Unlike thyrotropin, thyroid-stimulating antibodies do not activate phospholipase С in human thyroid slices. J Clin Invest 87:1634-1642.
  36. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont JE, Vassart G. 1993 Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-51.
  37. Tonacherra M, Van Sande J, Parma J, Duprez L, Cetani F, Costagliola S, Dumont JE, Vassart G. 1996 TSH receptor and disease. Clin Endocrinol 44:621-633.
  38. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G. 1995 Brief report: Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engi J Med 332:150-154.
  39. Duprez L, Parma J, Van Sande J, Allgeier A, Leclere J, Schvartz C, Delisle MJ, Decoulx M, Orgiazzi J, Dumont JE, Vassart G. 1994 Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 7:396-401.
  40. Tonacchera M, Van Sande J, Cetani F, Swillens S, Schvartz C, Winiszewski P, Portmann L, Dumont JE, Vassart G, Parma J. 1996 Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia. J Clin Endocrinol Metab 81:547-554.
  41. Sheline GE, McCormack К I960 Solitary hyperfuncytioning thyroid nodules. J Clin Endocrinol Metab 20:1401-1410.
  42. Kopp P, Kimura ET, Aeschimann S, Oestrelcher M, Tobler A, Fey MF, Studer H. 1994 Polyclonal and monoclonal thyroid nodules coexist within human multinodular goiters. J Clin Endocrinol Metab 79:134-139.
  43. Thomas R. 1978 Logical analysis of systems comprising feedback loops. J Ther Biol 73:631-656.
  44. Miiller WA. 1996 Pattern formation in the immortal hydra. TIG 12:91-96.
  45. Ledent C, Dumont JE, Vassart G, Parmentier M. 1992 Thyroid expression of an A2 adenosine receptor transgene induces thyroid hyperplasia and hyperthyroidism. EMBO J. 11:537-542.
  46. Michiels FM, Caillou В, Talbot M, Dessarps-Freichey F, Maunoury MT, Schiumberger M, Mercken L, Monier R, Feunteun J. 1994 Oncogenic potential of guanine nucleotide stimulatory factor alpha subunit in thyroid glands oftrans-genic mice. Proc Nati Acad Sci USA 91:10488-10492.
  47. Ledent С, Dumont JE, Vassart G, Parmentier M. 1991 Thyroid adeno-carcinomas secondary to tissue-specific expression of simian vims-40 large T-antigen in transgenic mice. Endocrinology 129:1391-1401.
  48. Karga H, Lee JK, Vickery AL, Thor A, Gaz RD , Jameson JL. 1991 Ras-oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73:832-836.
  49. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone 1, Delia Porta G, BergerN, Peix JL, Paulin C, Fabien N, Vecchio G, Jenkins RB, Fusco A. 1992 Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517-1522.
  50. Als C, Listewnik M, Roesler H, Bartkowiak E. 1995 Immunogenic and non-immunogenic hyperthyroidism. Recent trends in prealpine Switzerland and in coastal Poland, Nuklearmedizin 34:92-99.
  51. Paschke R. 1996 Constitutively activating TSH receptor mutations as the cause of toxic thyroid adenoma, multinodular toxic goiter and autosomal dominant non autoimmune hyperthyroidism. Exp Clin Endocrinology Diabetes 104 (Supp I.) 4: 129-132.
  52. Duprez L, Hermans J, VanSande J, Dumont JE, Vassart G, Parma J 1996. Two autonomous nodules of a patient with multinodular goiter harbor different activating mutations of the thyrotropm receptor gene. J Clin Endocrinol Metab 82:306-308.
  53. Corvilain В, Contempre В, Longombe АО, Goyens P, Gervy Decoster C, Lamy F, Vanderpas JB, Dumont JE. 1993 Selenium and the thyroid: How the relationship was established. Am J Clin Nutr 57:244S-248S.
  54. Wiseman H, Halliwell В. 1996 Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 313:17-29.
  55. Bjorkman U, Ekholm R 1995 Hydrogen peroxide degradation and glu-tathione peroxidase activity in cultures of thyroid cells. Mol Cell Endocrinol 111:99-107.
  56. Coclet J, Foureau F, Ketelbant P, Galand P, Dumont JE. 1989 Cell population kinetics in dog and human adult thyroid. Clin Endocrinol 31:655-665.
  57. Clugston G, Beaudry M, Delange F. 1996 Iodine induced thyrotoxicosis. Lancet 347:1051.
  58. Laurberg P. 1994 Iodine intake. What are we aiming at? J Clin Endocrinol Metab 79:17-19.
  59. Burgi H. 1996, personal communication, with kind permission.
  60. Dremier S, Coppee F, Delange F, Vassart G, Dumont JE, Van Sande J. 1996 Thyroid autonomy: Mechanism and clinical effects. J Clin Endocrinol Metab 81:4187-4193.